FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 329:703-709 September 2, 1993 Number 10 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Acute myocardial infarction is the most common cause of death in the United States and in almost all Western industrialized countries. Although unadjusted rates of mortality due to myocardial infarction in the United States have been falling in recent years, rates of mortality from all other causes have also been falling, so that the proportion of mortality caused by acute myocardial infarction has not changed. Mortality due to heart disease (mostly infarctions) accounted for 37 percent of all deaths for which a cause could be identified in 1950, for 39 percent in 1960, 1970, and 1980, and for 36 percent . . . [Full Text of this Article]

Coronary Thrombosis and Thrombolysis

Thrombolytic Agents

Adjunctive Agents for Thrombolysis

Aspirin and Other Antiplatelet Drugs

Heparin and Other Antithrombin Drugs

The Risks of Combination Regimens

Selection of Patients

Coronary Angioplasty

Conclusions

Source Information

From the Cardiology Division, Department of Internal Medicine, University of Texas Health Science Center and Hermann Hospital, and the Texas Heart Institute, St. Luke's Episcopal Hospital, Houston.

Address reprint requests to Dr. Anderson at the Cardiology Division, University of Texas Health Science Center, 6431 Fannin St., Houston, TX 77030.

References

Related Letters:

Thrombolytic Agents
Gurewich V.
Extract | Full Text  
N Engl J Med 1994; 330:291, Jan 27, 1994. Correspondence

This article has been cited by other articles:

• Alhadi, H.A., Fox, K.A.A. (2004). Do we need additional markers of myocyte necrosis: the potential value of heart fatty-acid-binding protein. QJM 97: 187-198 [Abstract] [Full Text]  
• Saturno, P. J., Felices, F., Segura, J., Vera, A., Rodriguez, J. J., ARIAM Project Group, (2000). Reducing Time Delay in the Thrombolysis of Myocardial Infarction: An Internal Quality Improvement Project. American Journal of Medical Quality 15: 85-93 [Abstract]  
• Yellon, D M, Baxter, G F (2000). Protecting the ischaemic and reperfused myocardium in acute myocardial infarction: distant dream or near reality?. Heart 83: 381-387 [Full Text]  
• Newburger, J. W, Burns, J. C (1999). Kawasaki disease. Vasc Med 4: 187-202 [Abstract]  
• Gurevitz, O., Goldfarb, A., Hod, H., Feldman, M., Shenkman, B., Varon, D., Eldar, M., Inbal, A. (1998). Recombinant von Willebrand Factor Fragment AR545C Inhibits Platelet Aggregation and Enhances Thrombolysis With rtPA in a Rabbit Thrombosis Model. Arterioscler. Thromb. Vasc. Bio. 18: 200-207 [Abstract] [Full Text]  
• Ravn, H. B., Kristensen, S. D., Hjortdal, V. E., Thygesen, K., Husted, S. E.ær (1997). Early Administration of Intravenous Magnesium Inhibits Arterial Thrombus Formation. Arterioscler. Thromb. Vasc. Bio. 17: 3620-3625 [Abstract] [Full Text]  
• Spaulding, C. M., Joly, L.-M., Rosenberg, A., Monchi, M., Weber, S. N., Dhainaut, J.-F. A., Carli, P. (1997). Immediate Coronary Angiography in Survivors of Out-of-Hospital Cardiac Arrest. NEJM 336: 1629-1633 [Abstract] [Full Text]  
• Collins, R., Peto, R., Baigent, C., Sleight, P. (1997). Aspirin, Heparin, and Fibrinolytic Therapy in Suspected Acute Myocardial Infarction. NEJM 336: 847-860 [Full Text]  
• Jensen, L. T., Host, N. B. (1997). Collagen: scaffold for repair or execution. Cardiovasc Res 33: 535-539  
• Garcia, J. H., Lassen, N. A., Weiller, C., Sperling, B., Nakagawara, J. (1996). Ischemic Stroke and Incomplete Infarction. Stroke 27: 761-765 [Abstract] [Full Text]  
• Collen, D. (1996). Fibrin-Selective Thrombolytic Therapy for Acute Myocardial Infarction. Circulation 93: 857-865 [Full Text]  
• Hussain, K.M.A., Gould, L., Sosler, B., Bharathan, T., Reddy, C.V.R. (1996). Clinical Science Review: Current Aspects of Thrombolytic Therapy in Women with Acute Myocardial Infarction. ANGIOLOGY 47: 23-33 [Abstract]  
• Vanderschueren, S., Barrios, L., Kerdsinchai, P., Van den Heuvel, P., Hermans, L., Vrolix, M., De Man, F., Benit, E., Muyldermans, L., Collen, D., Van de Werf, F. (1995). A Randomized Trial of Recombinant Staphylokinase Versus Alteplase for Coronary Artery Patency in Acute Myocardial Infarction. Circulation 92: 2044-2049 [Abstract] [Full Text]  
• Tait, J. F., Engelhardt, S., Smith, C., Fujikawa, K. (1995). Prourokinase-Annexin V Chimeras. J. Biol. Chem. 270: 21594-21599 [Abstract] [Full Text]  
• Casscells, W. (1995). Growth Factor Therapies for Vascular Injury and Ischemia. Circulation 91: 2699-2702 [Full Text]  
• Garcia, J. H., Wagner, S., Liu, K.-F., Hu, X.-j. (1995). Neurological Deficit and Extent of Neuronal Necrosis Attributable to Middle Cerebral Artery Occlusion in Rats : Statistical Validation. Stroke 26: 627-635 [Abstract] [Full Text]  
• Gurewich, V. (1994). Thrombolytic Agents. NEJM 330: 291-291 [Full Text]  
• Fuster, V. (1993). Coronary Thrombolysis -- A Perspective for the Practicing Physician. NEJM 329: 723-725 [Full Text]